tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Depression Treatment
PremiumCompany AnnouncementsCompass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Depression Treatment
1M ago
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Treatment-resistant Depression
Premium
Company Announcements
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Treatment-resistant Depression
2M ago
Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support
Premium
Ratings
Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support
2M ago
Compass Pathways’ COMP360 Study: A New Hope for Treatment-resistant Depression?
PremiumCompany AnnouncementsCompass Pathways’ COMP360 Study: A New Hope for Treatment-resistant Depression?
2M ago
Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright
Premium
The Fly
Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright
2M ago
Compass Pathways’ Phase III Study on COMP360: A Potential Breakthrough in Treating Depression
Premium
Company Announcements
Compass Pathways’ Phase III Study on COMP360: A Potential Breakthrough in Treating Depression
2M ago
Psychedelic: Filament reports compassionate use approval for psilocybin
PremiumThe FlyPsychedelic: Filament reports compassionate use approval for psilocybin
2M ago
Compass Pathways reports Q2 EPS (41c) vs. (56c) last year
Premium
The Fly
Compass Pathways reports Q2 EPS (41c) vs. (56c) last year
2M ago
Compass Pathways’ Psilocybin Study: A Potential Game-Changer for Depression Treatment
Premium
Company Announcements
Compass Pathways’ Psilocybin Study: A Potential Game-Changer for Depression Treatment
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100